Click here if you have patients on the Repatha® prefilled single-dose syringe and need additional guidance on how to transition patients to a different device.
×Repatha® is indicated:
For US healthcare professionals
Repatha® is now available through AmgenNowTM, a direct-to-patient program. Learn more here.
Inclusion on formulary does not imply superior clinical efficacy or safety.
of commercial claims
are approved for
Repatha® 1,†
of Medicare claims are
approved for
Repatha® 1,†
of Medicaid claims are
approved for
Repatha® 1,†
The majority of patients with commercial insurance do not require a Prior Authorization or only have an e-step requirement2,‡
Repatha® may cost your patients less than you think
for a 1-month supply or $50 for a 3-month supply with the Repatha® Co-Pay card for eligible commercially insured patients3,§
for ~84% of
Repatha®
prescriptions3,**,††
for ~99% of
Repatha®
prescriptions3,‡‡
*Includes commercial, health exchange, Medicaid, and Medicare lives, as of February 2026, based on MMIT data. Inclusion on formulary does not imply superior clinical efficacy or safety. This information is subject to change without notice. For the most up-to-date and complete information regarding coverage of Repatha®, please contact the relevant payer directly. Individual insurance requirements may vary.
†Based on IQVIA claims data from 1/1/2025 to 12/26/2025. Approval rates identify the percent of all submitted new claims regardless of prior authorization requirements, if any, that have been approved during 1/1/2025 to 12/26/2025 across Commercial, Medicare, and Medicaid data. Number of attempts for approval and turnaround time may vary by patient and payer. New claims are inclusive of Repatha New to Brand patients and existing Repatha patients with new prescriptions. This information is directional and should not be interpreted as absolute values. This information is subject to change without notice; check the applicable payer policy for the most up-to-date information.
‡ Based on IQVIA claims data from 1/1/2025 to 12/31/25 using Commercial and Medicare data. Patient out-of-pocket costs and insurance requirements may vary.
§Eligibility criteria and program maximums apply. Co-pay support for a 3-month supply depends on the patient's insurance, as some plans may impose quantity or dispensing limitations. Please see full Terms and Conditions at https://www.repatha.com/copaytcs
**Based on IQVIA claims data from 1/1/2025 to 12/31/25 using Medicare data. Patient out-of-pocket costs and insurance requirements may vary.
††The patient’s out-of-pocket costs may vary throughout the year, depending on which phase of the Part D benefit the patient is currently in.
‡‡Based on IQVIA claims data from 1/1/2025 to 12/31/25 using Medicaid data. Patient out-of-pocket costs and insurance requirements may vary.
References: 1. Data on file, Amgen; [1]; 2026. 2. Data on file, Amgen; [2]; 2026. 3. Data on file, Amgen; [3]; 2026.